Pulse Biosciences
Hayward
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $233.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2023)
- Ticker: nasdaq:PLSE
- Website: pulsebiosciences.com
- Phone: 650.697.3939
Industries & Categories
Health Care, Medical, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pulse-biosciences-78895 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.